CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

Stock Information for TCR2 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TCR2 Therapeutics Inc.

Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECT, NATI, CTIC, USX
CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, CTIC, DFFN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTIC, FRG, MMP
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, HMPT, CTIC
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - MMP, CTIC, HMPT, AMED
Moore Kuehn Encourages HMPT, ABST, CTIC and FRG Investors to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.